Biovico becomes a leader of intraarticular hyaluronic acids

Friday March 17th, 2017

Biovico company received a grant for the development of hyaluronic acid with added value under the program “szybka ścieżka” NCBR.

The aim of the project is to develop a new generation proprietary product, and the entirety of works will be carried out on the premises of our own laboratory located in the Pomeranian Science and Technology Park in Gdynia. Modern laboratory together with the specialized scientific staff enable self-realization of the entire process of creating a new product.

Today Biovico is the undisputed leader in intraarticular hyaluronic acids in Poland. Moreover, the development of a new product opens even wider opportunities for the company in foreign markets.

The main product from the company portfolio – Biolevox HA - supplies over 50% of the Polish market and is successfully distributed to foreign markets. Last year alone, the product developed better than the whole market of intraarticular hyaluronic acids in Poland. The sales dynamics show that our Biolevox Ha increased by 55%, while the entire market increased by 21%.

When we started distributing our product in 2012 the market share was only 0.2%. The past 4 years have shown that unmatched quality of the preparation convinced both physicians and patients, gaining recognition of over 50% of the current intraarticular hyaluronic acid market in Poland.

The funding received for the development of hyaluronic acid and the development of a new generation product is important for Biovico, as its primary goal and mission translate into providing patients with the highest quality medical devices and innovative solutions for every stage of orthopedic and rheumatic diseases.